SCHEMBL20117

SCHEMBL20117

CSc1nc(NCCC(C)C)c2nc[nH]c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
SLC29A1 Q99808 1/20 0.37
UTS2R Q9UKP6 1/20 0.34
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CDK5 Q00535 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
JAK1 P23458 3/20 0.32
JAK3 P52333 3/20 0.32
JAK2 O60674 2/20 0.32
TYK2 P29597 2/20 0.32
MAPK14 Q16539 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561771 0.87 CYP1A2 (0.36) CYP1A2CYP2D6CYP3A4CYP2C19SLC29A1
SCHEMBL16146619 0.82 SLC29A1 (0.40) CYP1A2CYP2D6SLC29A1UTS2RCDK2
SCHEMBL16146189 0.81 CYP1A2 (0.42) CYP1A2SLC29A1UTS2RCDK2ALDH1A1
SCHEMBL21788563 0.81 SLC29A1 (0.39) CYP1A2CYP2D6SLC29A1UTS2RALDH1A1
SCHEMBL16145765 0.81 SLC29A1 (0.42) CYP1A2CYP2D6SLC29A1UTS2RALDH1A1
SCHEMBL20118 0.80 CYP1A2 (0.70) CYP1A2CYP2D6CYP3A4CYP2C19CDK2
SCHEMBL29392628 0.80 CYP1A2 (0.70) CYP1A2CYP2D6CYP3A4CYP2C19CDK2
SCHEMBL3241687 0.80 PPARG (0.34) CYP1A2CYP2D6CYP3A4CYP2C19CCNE1
SCHEMBL17372396 0.76 LMNA (0.42) CYP1A2CYP2D6CYP3A4CYP2C19KDM4E
SCHEMBL11831291 0.76 CXCR2 (0.38) CYP1A2CYP2D6CYP3A4CYP2C19UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694524-B1 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES US HEALTH (US) 2016-05-18 EP claimed
US-9284343-B2 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-03-15 US claimed
EP-2567964-B1 Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection AGILENT TECHNOLOGIES INC (US) 2015-02-11 EP claimed
US-20140051846-A1 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) 2014-02-20 US claimed
EP-2694524-A1 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2014-02-12 EP claimed
WO-2012138530-A1 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-10-11 WO claimed
US-7807356-B2 Labeled nucleotide composition AGILENT TECHNOLOGIES, INC. (US) 2010-10-05 US claimed
US-7524942-B2 Labeled nucleotide composition AGILENT TECHNOLOGIES, INC. (US) 2009-04-28 US claimed
US-20080124708-A1 Labeled nucleotide composition AGILENT TECHNOLOGIES, INC. 2008-05-29 US claimed
US-20070212697-A1 Labeled nucleotide composition AGILENT TECHNOLOGIES, INC. 2007-09-13 US claimed
EP-4748940-A2 DE NOVO SYNTHESISED GENE LIBRARIES Twist Bioscience Corporation (US) 2026-05-27 EP disclosed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO disclosed
US-20260138111-A1 DE NOVO SYNTHESIZED GENE LIBRARIES Twist Bioscience Corporation (US) 2026-05-21 US disclosed
EP-4743580-A1 EFFICIENT TRANSGENE-FREE GENOME EDITING IN PLANTS IN THE T0 GENERATION BASED ON A CO-EDITING STRATEGY University of Florida Research Foundation, Incorporated (US) 2026-05-20 EP disclosed
EP-3790985-B1 METHODS OF SYNTHESIZING A POLYNUCLEOTIDE ARRAY USING PHOTACTIVATED AGENTS VIBRANT HOLDINGS LLC (US) 2026-04-15 EP disclosed
US-6222030-B1 CONDENSING HYDROXY GROUP OF BOUND OLIGONUCLEOTIDE OR NUCLEOSIDE WITH NUCLEOSIDE PHOSPHORAMIDITE HAVING CARBONATE-PROTECTED HYDROXYL GROUP, TREATING WITH DEPROTECTING AGENT ALSO OXIDIZES PHOSPHITE TRIESTER LINKAGE AGILENT TECHNOLOGIES, INC. 2001-04-24 US disclosed
WO-2001014401-A1 NUCLEOSIDE PYROPHOSPHATE AND TRIPHOSPHATE ANALOGS AND RELATED COMPOUNDS AS THERAPEUTIC AGENTS SRI INTERNATIONAL (US) 2001-03-01 WO disclosed
WO-2000012524-A1 PURIFICATION OF OLIGOMERS USING DUAL-END SELECTION BAYER CORPORATION (US) 2000-03-09 WO disclosed
EP-0984021-A2 Synthesis of oligonucleotides Hewlett-Packard Company (US) 2000-03-08 EP disclosed
EP-0147689-B1 A METHOD OF INDUCING ANTITUMOR IMMUNOCYTES, AND A PROCESS FOR PRODUCING ANTITUMOR IMMUNOCYTES AND ANTITUMOR IMMUNOCYTES PRODUCED BY THE PROCESS Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1990-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124708-A1 Labeled nucleotide composition RNGTT, RNMT, NOP2 CYP1A2 3227/4885CYP2D6 2787/4885CYP3A4 3828/4885
US-20070212697-A1 Labeled nucleotide composition RNGTT, RNMT, NOP2 CYP1A2 3227/4885CYP2D6 2787/4885CYP3A4 3828/4885
US-20260138111-A1 DE NOVO SYNTHESIZED GENE LIBRARIES POLM, DNMT3A, POLN CYP1A2 2361/4885CYP2D6 1210/4885CYP3A4 2960/4885
US-20140051846-A1 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES NSUN2, RNGTT, RNMT CYP1A2 3150/4885CYP2D6 2529/4885CYP3A4 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.